User login
As mandated in the FDA Safety and Innovation Act (FDASIA), the FDA has published a final rule requiring all manufacturers of certain medically important drug and biologic products to give the FDA early notification of potential drug shortages and to report the reasons for potential shortages. Acting FDA Commissioner Stephen Ostroff, MD, wrote about this and other milestones in the implementation of the law, in a recent blog. http://blogs.fda.gov/fdavoice/index.php/2015/07/celebrating-the-3rd-anniversary-of-the-fda-safety-and-innovation-act/
As mandated in the FDA Safety and Innovation Act (FDASIA), the FDA has published a final rule requiring all manufacturers of certain medically important drug and biologic products to give the FDA early notification of potential drug shortages and to report the reasons for potential shortages. Acting FDA Commissioner Stephen Ostroff, MD, wrote about this and other milestones in the implementation of the law, in a recent blog. http://blogs.fda.gov/fdavoice/index.php/2015/07/celebrating-the-3rd-anniversary-of-the-fda-safety-and-innovation-act/
As mandated in the FDA Safety and Innovation Act (FDASIA), the FDA has published a final rule requiring all manufacturers of certain medically important drug and biologic products to give the FDA early notification of potential drug shortages and to report the reasons for potential shortages. Acting FDA Commissioner Stephen Ostroff, MD, wrote about this and other milestones in the implementation of the law, in a recent blog. http://blogs.fda.gov/fdavoice/index.php/2015/07/celebrating-the-3rd-anniversary-of-the-fda-safety-and-innovation-act/
